Remedium Capital Partners, LLC reported 5 positions worth $373.76M for the quarter ended Jun 30, 2026, up 38.1% on the prior quarter. It opened 0 new positions, added to 0, trimmed 2 and exited 0. Its largest holding is Oruka Therapeutics, Inc. at 39.9% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORKA Oruka Therapeutics, Inc. | Healthcare | 1.57M | $149.00M | 39.87% | -323.5K | -17.1% | Reduced | 2.49% |
| 2 | SYRE Spyre Therapeutics, Inc. | Healthcare | 1.46M | $129.99M | 34.78% | -443.2K | -23.2% | Reduced | 1.73% |
| 3 | DMRA Damora Therapeutics, Inc. | Healthcare | 2.05M | $53.20M | 14.23% | 0 | 0.0% | Unchanged | 3.31% |
| 4 | JBIO Jade Biosciences, Inc. | Healthcare | 1.58M | $35.06M | 9.38% | 0 | 0.0% | Unchanged | 2.48% |
| 5 | CBIO Crescent Biopharma, Inc. | Healthcare | 361.3K | $6.50M | 1.74% | 0 | 0.0% | Unchanged | 1.18% |
Tip. Select a row to see that position’s full history at Remedium Capital Partners.
As of its Q2 2026 13F filing, Remedium Capital Partners, LLC’s five largest positions were Oruka Therapeutics, Inc. (ORKA) at 39.9%, Spyre Therapeutics, Inc. (SYRE) at 34.8%, Damora Therapeutics, Inc. (DMRA) at 14.2%, Jade Biosciences, Inc. (JBIO) at 9.4%, Crescent Biopharma, Inc. (CBIO) at 1.7% of the reported portfolio.
Remedium Capital Partners, LLC reported a 13F portfolio worth $373.76M across 5 positions for Q2 2026. That is up 38.1% from the previous quarter.
Its largest sales by value were Spyre Therapeutics, Inc. ($39.34M), Oruka Therapeutics, Inc. ($30.78M). It exited 0 positions entirely.
From the Form 13F-HR reports Remedium Capital Partners, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.